Case report: Major pathologic response induced by neoadjuvant treatment using BRAF and MEK inhibitors in a patient with stage IIIA lung adenocarcinoma harboring BRAF V600E-mutation

Targeted therapy has achieved great success in advanced non-small lung cancer (NSCLC) with driver genes, and neoadjuvant-targeted therapy is increasingly being investigated. Although neoadjuvant-targeted therapy with EGFR-TKI and ALK-TKI showed good efficacy, there is no report of neoadjuvant-target...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Chaoyuan, Lu, Min, Yang, Yang, Wang, Xiang, Ma, Fang, Liu, Xianling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393753/
https://www.ncbi.nlm.nih.gov/pubmed/36003777
http://dx.doi.org/10.3389/fonc.2022.961539

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393753/
https://www.ncbi.nlm.nih.gov/pubmed/36003777
http://dx.doi.org/10.3389/fonc.2022.961539

Ejemplares similares